China Medical Wins Approval for Breast Cancer HER-2 FISH Probe
Posted on: Thursday, 13 November 2008, 09:00 CST
China Medical Technologies, a medical device company, has received approval for its breast cancer HER-2 FISH probe from the State Food and Drug Administration in China.
According to the company, the HER-2 fluorescent in situ hybridization (FISH) probe is designed to detect amplification of the Her-2 gene in human breast cancer tissue.
HER-2, also known as HER-2/neu, is a gene that is notable for its prognostic role as well as the target of herceptin, a drug for breast cancer treatment. Herceptin is said to be effective in cancer patients whose Her-2 gene is over-expressed.
Xiaodong Wu, chairman and CEO of China Medical Technologies. "The approval enables us to initiate commercial promotion of our Fish probes. We believe that the commencement of commercial promotion will increase public awareness of the clinical benefits of FISH probes, which in turn will result in long term sustainable growth of the recurring sales of our FISH probes."
Source: Datamonitor
Related Articles
- China's Breast Cancer Drug Market Will Grow From $165 Million in 2008 to $298 Million In 2013
- Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
- Breast Cancer Action Sues to End Gene Patenting
- Nexavar Approved for Liver Cancer in China
- Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
- China Lunar Probe to Meet Moon Eclipse
- Latent Demand for Salted, Sun-Dried, and Pickled Fish in Greater China
- Aurora Breast MRI Utilized for Screening Patients at High Risk for Breast Cancer at Victory Breast Diagnostics and Women's Imaging in Texas
- Cancer Society Recommends Breast MRIs
- New Technology Improving Breast Cancer Detection at Breast Health Institute
 |
 |
User Comments (0)
RSS Feeds